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Abstract: Objectives: There is debate on whether the use of third-generation cephalosporins (3GC)
increases the risk of clinical failure in bloodstream infections (BSIs) caused by chromosomally-mediated
AmpC-producing Enterobacterales (CAE). This study evaluates the impact of definitive 3GC therapy
versus other antibiotics on clinical outcomes in BSIs due to Enterobacter, Serratia, or Citrobacter species.
Methods: This multicenter, retrospective cohort study evaluated adult hospitalized patients with
Antibiotics 2020, 9, 254; doi:10.3390/antibiotics9050254 www.mdpi.com/journal/antibiotics
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BSIs secondary to Enterobacter, Serratia, or Citrobacter species from 1 January 2006 to 1 September
2014. Definitive 3GC therapy was compared to definitive therapy with other non-3GC antibiotics.
Multivariable Cox proportional hazards regression evaluated the impact of definitive 3GC on
overall treatment failure (OTF) as a composite of in-hospital mortality, 30-day hospital readmission,
or 90-day reinfection. Results: A total of 381 patients from 18 institutions in the southeastern United
States were enrolled. Common sources of BSIs were the urinary tract and central venous catheters
(78 (20.5%) patients each). Definitive 3GC therapy was utilized in 65 (17.1%) patients. OTF occurred in
22/65 patients (33.9%) in the definitive 3GC group vs. 94/316 (29.8%) in the non-3GC group (p = 0.51).
Individual components of OTF were comparable between groups. Risk of OTF was comparable with
definitive 3GC therapy vs. definitive non-3GC therapy (aHR 0.93, 95% CI 0.51–1.72) in multivariable
Cox proportional hazards regression analysis. Conclusions: These outcomes suggest definitive
3GC therapy does not significantly alter the risk of poor clinical outcomes in the treatment of BSIs
secondary to Enterobacter, Serratia, or Citrobacter species compared to other antimicrobial agents.
Keywords: bacteremia; cephalosporins; sepsis; beta-lactamases; AmpC; carbapenems
1. Introduction
Antimicrobial resistance is an increasingly prevalent problem and a substantial contributor
to the global disease burden and patient mortality [1]. In particular, beta-lactamase-mediated
resistance has emerged as a major threat to patient care. These enzymes may be produced from
chromosomal genes or from mobile genetic elements (i.e., transposons, plasmids). Among the
chromosomally-mediated beta-lactamases, the AmpC family represents one of the most commonly
encountered resistance enzymes [2]. These beta-lactamases are characteristically found in Enterobacter,
Serratia, or Citrobacter spp. [2,3]. Expression of these enzymes is a complex process regulated by
transcription factors (AmpR) and regulatory enzymes (AmpD), which work to promote or reduce
enzyme production, respectively. Induction of these enzymes may occur following exposure to certain
beta-lactams. Additionally, mutations in AmpD, and less commonly AmpR, lead to overexpression of
these enzymes, conferring resistance to most beta-lactams, including third-generation cephalosporins
(3GC) [2–4]. Clinical laboratories do not have a standard detection method for AmpC overproduction
among Enterobacterales, leading to a potential underestimation of both the prevalence and degree
of expression of this resistance mechanism. Prior data suggest the on-therapy emergence of 3GC
resistance can occur despite initial in vitro susceptibility. Complicating this controversy is a relative
dearth of clinical evidence to guide the treatment of non-Enterobacter AmpC-producing organisms [5–9].
These data highlight the continued controversy surrounding the optimal antimicrobial approach for
infections caused by AmpC-producing organisms [10,11].
Many clinicians avoid the utilization of 3GC due to the potential risk of inducing AmpC
beta-lactamases [12]. Carbapenems may be considered the current drug of choice; however, alternatives
such as cefepime may also be efficacious [12]. Cefepime demonstrates some stability in the presence
of AmpC enzymes and is able to achieve high periplasmic concentrations owing to its zwitterionic
structure [2]. Emerging concerns regarding overutilization of carbapenems and antipseudomonal
beta-lactams underscore the need to better define the utility of 3GC, such as ceftriaxone, in the
management of AmpC-producing organisms [13–15]. The purpose of this study is to compare the risk
of overall treatment failure (OTF) with definitive 3GC therapy compared to other antibiotic therapy
in patients with bloodstream infections (BSIs) due to chromosomally-mediated AmpC-producing
Enterobacterales (CAE).
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2. Results
2.1. Participants
Overall, 507 patients with a BSI secondary to Enterobacter, Serratia, or Citrobacter spp. from 1
January 2006 to 1 September 2014 were screened for study inclusion. Of these, 126 patients were
excluded, primarily due to missing data (Figure 1). Of 381 patients enrolled in the study, 65 patients
received definitive 3GC therapy, and 316 patients received other antimicrobial agents for definitive
therapy. The study population was generally similar between 3GC vs. non-3GC groups (Table 1).
Median age was 60 years, and approximately half of the patients were African American. Urinary tract
or central venous catheter (CVC) were the most common sources of BSIs, jointly representing 41.0%
(156) of cases. Charlson comorbidity index score was comparable between 3GC and non-3GC groups
(median 3 vs. 4, respectively, p = 0.98). The 3GC group had significantly more patients with renal
dysfunction (chronic kidney disease 33.9% vs. 21.2%, p = 0.03; median creatinine clearance 45 mL/min
vs. 56 mL/min, p = 0.04). Conversely, the 3GC group had significantly fewer males (49.2% vs. 63.9%,
p = 0.03), fewer respiratory sources of BSIs (4.6% vs. 13.3%, p = 0.049), and lower severity of illness
(ICU admissions 29.2% vs. 45.6%, p = 0.02; median Pitt Bacteremia score 2 vs. 3, p = 0.04).
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Figure 1. Flow diagra of subject enrollment.
Enterobacter spp. were the most common bloodstream isolates (62.5%), followed by Serratia spp.
(27.3%) and Citrobacter spp. (10.2%). Table 2 describes the number of isolates by treatment group.
The overall distribution of CAE organisms between groups was significantly different (p = 0.03), with a
numerically higher proportion of Enterobacter spp. in the non-3GC group and Serratia or Citrobacter spp.
in the 3GC group.
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Table 1. Baseline characteristics of patients on definitive therapy with third-generation cephalosporin
(3GC) versus other antimicrobial agents.
Characteristic Definitive 3GC Therapy
a
N = 65
Definitive Non-3GC Therapy a
N = 316 p-Value
Age, y (median (IQR)) 59 (46.5–68.0) 60 (47.8–70.0) 0.989
Male 32 (49.2) 202 (63.9) 0.027
Weight, kg (median (IQR)) 80 (71.0–102.3) 85 (70.0–103.0) 0.884
Race/Ethnicity
0.308
Black 33 (50.8) 130 (41.4)
White 29 (44.6) 175 (55.4)
Other/Unknown 3 (4.6) 11 (3.5)
Intensive Care Unit Admission 19 (29.2) 144 (45.6) 0.016
CrCl, mL/min (median (IQR)) 45 (21.9–85.4) 56 (28.7–86.7) 0.036
Penicillin/Cephalosporin Allergy 8 (12.3) 41 (13.0) 0.884
Charlson Comorbidity Index (median (IQR)) 3 (2.0–6.0) 4 (2.0–6.0) 0.984
Source of Infection
Central Venous Catheter 17 (26.2) 61 (19.3) 0.213
Urinary Tract 15 (23.1) 63 (19.9) 0.568
Skin- or Skin Structure-Related 9 (13.9) 35 (11.1) 0.525
Intra-Abdominal 6 (9.2) 34 (10.8) 0.714
Respiratory 3 (4.6) 42 (13.3) 0.049
Other 6 (9.2) 16 (5.1) 0.237
Unknown Source 9 (13.9) 76 (24.1) 0.072
Site of Acquisition
0.275
Hospital-Acquired 27 (42.2) 160 (50.6)
Healthcare-Associated 21 (32.8) 102 (32.3)
Community-Acquired 16 (25.0) 54 (17.1)
Pitt Bacteremia Score (median (IQR)) 2 (1.0–3.0) 3 (1.0–4.0) 0.043
Adequate Empiric Therapy 60 (92.3) 291 (92.1) 0.952
Abbreviations: 3GC, third-generation cephalosporin; IQR, interquartile range; CrCl, creatinine clearance. a Data
reported as n (%) unless otherwise noted.




Definitive 3GC Therapy a,b
N = 65
Definitive Non-3GC Therapy a,b
N = 316
Enterobacter spp. 238 (62.5) 33 (50.7) 205 (64.8)
E. cloacae 142 (37.3) 19 (29.2) 123 (38.9)
E. aerogenes 82 (21.5) 14 (21.5) 68 (21.5)
Other Enterobacter spp. 14 (3.7) 0 (0) 14 (4.4)
Serratia spp. 104 (27.3) 21 (32.3) 83 (26.2)
S. marcescens 100 (26.2) 19 (29.2) 81 (25.6)
Other Serratia spp. 4 (1.0) 2 (3.1) 2 (0.6)
Citrobacter spp. 39 (10.2) 11 (16.9) 28 (8.8)
C. freundii 21 (5.5) 8 (12.3) 13 (4.1)
Other Citrobacter spp. 18 (4.7) 3 (4.6) 15 (4.7)
a Data reported as n (%). b p < 0.05 when evaluating the distribution of Enterobacter, Serratia, and Citrobacter spp
between both groups.
Overall antibiotic usage was evaluated (Table 3); the mean number of antibiotic agents used was
slightly higher in the 3GC group vs. non-3GC group (3.5 vs. 3.0 antibiotic agents, respectively, p = 0.005).
Inpatient treatment was continued for a median of 10.3 days in the 3GC group, compared to 8.8 days in
the non-3GC group (p = 0.58). Definitive therapy with 3GCs (primarily ceftriaxone) in the 3GC group
composed a median of 70% of the inpatient definitive treatment duration. Thus, for every 7 days of
inpatient definitive therapy, a 3GC was used for approximately 5 of those days in most cases (compared
to 0 days in the non-3GC group). Among the 3GC group, 64% of ceftriaxone was ordered at a dose of
1 g IV and 36% of ceftriaxone was ordered as 2 g IV, with either dose typically given once daily. Patients
in the non-3GC group most commonly received fluoroquinolones, carbapenems, or extended-spectrum
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penicillins for definitive therapy. Doses varied, but the vast majority were in accordance with package
insert dosing recommendations for each respective agent. Baseline non-susceptibility rates to 3GC
were 7.7% and 17.7% in the 3GC and non-3GC groups, respectively (p = 0.045). Approximately half of
the patients were discharged from the hospital on antibiotic therapy (52.3% vs. 51.1%, p = 0.86).
Table 3. Antibiotic utilization by therapy group.
Variable Definitive 3GC Therapy
a
N = 65
Definitive Non-3GC Therapy a
N = 316 p-Value
Number of Inpatient Antibiotics Used (mean (SD)) 3.5 (1.6) 3.0 (1.4) 0.005
Antibiotic Class
Extended-Spectrum Penicillins b 30 (46.2) 187 (59.2) 0.054
Third-Generation Cephalosporins 65 (100) 31 (9.8) c <0.001
Fourth-Generation Cephalosporins 12 (18.5) 83 (26.3) 0.185
Carbapenems 16 (24.6) 115 (36.4) 0.069
Fluoroquinolones 25 (38.5) 158 (50.0) 0.090
Aminoglycosides 12 (18.5) 54 (17.1) 0.790
Other Antibiotics 40 (61.5) 182 (57.6) 0.580
Inpatient Gram-Negative Antibiotic Duration, days (median (IQR)) 10.3 (5.7–15.6) 8.8 (5.0–13.9) 0.578
Empiric Duration 2.8 (2.3–3.0) 2.7 (2.2–3.0) 0.470
Definitive Duration 7.4 (3.5–12.9) 5.8 (2.4–11.0) 0.620
Inpatient 3GC Duration, days (median (IQR)) 4.4 (2.8–7.4) 0.5 (0.5–1.6) <0.001
Empiric 3GC Duration 2.5 (0.9–3.0) 0.5 (0.5–1.6) 0.002
Definitive 3GC Duration 3.3 (1.4–6.5) – –
Proportion of Time 3GC Used for Definitive Inpatient Therapy (median (IQR)) 0.7 (0.3–1.0) – –
Adequate Definitive Therapy d 0.487
Yes 63 (98.4) 281 (95.3)
No 1 (1.6) 14 (4.7)
Number of Patients Discharged on Antibiotics 34 (52.3) 161 (51.1) 0.861
Abbreviations: 3GC, third-generation cephalosporin; IQR, interquartile range; SD, standard deviation. a Data
reported as n (%), unless otherwise noted. b Including extended-spectrum penicillins and beta-lactamase inhibitor
combinations. c Empiric 3GC use only (no definitive 3GC use) d Due to missing data, N = 64 in definitive 3GC
therapy group and N = 295 in definitive non-3GC therapy group
2.2. Clinical Outcomes
The crude estimate of the primary endpoint of OTF was comparable between the definitive
3GC and non-3GC therapy groups (33.9% vs. 29.8%, respectively, p = 0.51). The components of the
composite endpoint between definitive 3GC and non-3GC therapy groups, i.e., in-hospital mortality,
hospital readmission within 30 days, and reinfection within 90 days, were also comparable (Table 4).
The median length of hospital stay was 12.7 vs. 14.2 days in the definitive 3GC and non-3GC therapy
groups, respectively (p = 0.16).
Table 4. Clinical outcomes by therapy group.
Outcome Definitive 3GC Therapy
a
N = 65
Definitive Non-3GC Therapy a
N = 316 p-Value
Overall Treatment Failure 22 (33.8) 94 (29.7) 0.513
In-Hospital Mortality 4 (6.2) 33 (10.4) 0.302
Hospital Readmission within 30 Days 15 (23.1) 53 (17.0) 0.245
Reinfection within 90 Days 6 (9.2) 16 (5.1) 0.232
30-Day Mortality 4 (6.2) 27 (8.5) 0.521
Length of Hospital Stay, days (median (IQR)) 12.7 (7.7–32.6) 14.2 (6.7–34.9) 0.158
Abbreviations: 3GC, third-generation cephalosporin; IQR, interquartile range. a Data reported as n (%), unless
otherwise noted.
The univariable Cox proportional hazards regression model estimated comparable odds of OTF
with the definitive 3GC therapy compared to definitive non-3GC therapy (odds ratio (OR) 1.11, 95%
confidence interval (CI) 0.70–1.76, p = 0.66). Kaplan–Meier curves for OTF by therapy group were
comparable (Figure 2, log rank p = 0.66). The final multivariable Cox proportional hazards regression
model included definitive 3GC therapy and additional covariates such as adequate empiric therapy,
male sex, creatinine clearance, source of infection, and site of acquisition (Table 5). This analysis
suggested definitive 3GC therapy was not independently associated with OTF (adjusted OR 0.93,
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95% CI 0.51–1.72, p = 0.83) when compared to definitive non-3GC therapy. There was a trend of
higher OTF in patients with malignancy, but it did not achieve statistical significance. No other
significant predictors of OTF were identified. Of the 37 patients with an evaluable repeat positive blood
culture (10% of the total study population), two isolates demonstrated the emergence of antimicrobial
resistance, both in the non-3GC antibiotic group. As a brief post hoc sensitivity analysis, the crude
estimate of OTF was evaluated among the subgroup of patients with Enterobacter spp. and was
comparable between the definitive 3GC and non-3GC therapy groups (24.2% (8/33) vs. 29.2% (60/205),
p = 0.55).
Table 5. Multivariable Cox proportional hazards regression model for overall treatment failure.
Variable Adjusted HR 95% CI p-Value
Definitive 3GC Therapy a 0.93 0.51–1.72 0.825
Adequate Empiric Therapy 0.40 0.12–1.32 0.132
Male Sex 0.67 0.42–1.08 0.097
CrCl, per mL/min increase 1.00 0.99–1.08 0.223
Source of Infection other than Urinary Tract or CVC 1.04 0.65–1.67 0.858
Site of Acquisition
Community-Acquired Ref. - -
Healthcare-Associated 0.85 0.46–1.57 0.596
Hospital-Acquired 1.13 0.59–2.17 0.714
Malignancy 1.71 0.98–2.99 0.059
Liver Cirrhosis 1.88 0.80–4.46 0.151
Pitt Bacteremia Score, per point increase 1.04 0.93–1.17 0.488
Penicillin/Cephalosporin Allergy 1.30 0.80–2.13 0.292
Abbreviations: HR, hazard ratio; CI, confidence interval; 3GC, third-generation cephalosporin; CrCl, creatinine
clearance; CVC, central venous catheter. a Definitive non-3GC therapy as the referent group.
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3. Discussion
Reports of higher treatment failure rates in the literature associated with 3GC therapy for
Enterobacter spp. BSIs have led many clinicians to advise against the use of third-generation
cephalosporins in infections with these pathogens, regardless of in vitro susceptibility [12]. This may
encourage the utilization of carbapenems for definitive treatment of BSIs due to Enterobacter spp.
and other CAE. Although the effectiveness of some carbapenem-sparing antimicrobial options has
been recently demonstrated, all of the agents utilized were antipseudomonal beta-lactams, such as
cefepime or piperacillin–tazobactam [10,16]. This has limited the ability to de-escalate patients receiving
antipseudomonal beta-lactams in even the most robust antimicrobial stewardship settings [17]. In an
era of increasing antimicrobial resistance and reporting of antimicrobial utilization and resistance to
the National Healthcare Safety Network, antimicrobial stewardship programs have been searching for
safe strategies to reduce unnecessary utilization of carbapenems and antipseudomonal beta-lactams.
This study sought to qualify the consequence of using 3GCs as definitive therapy for BSIs due to
organisms frequently associated with the production of AmpC beta-lactamases. The majority of
patients in the current study received ceftriaxone, a beta-lactam without antipseudomonal coverage.
In contrast to previous literature, our study did not reveal a significant difference in overall treatment
failure when 3GCs were used as definitive therapy for BSIs with these pathogens. Overall treatment
failure was similar in both treatment arms regardless of antimicrobial selection and with an apparent
low risk of emergence of resistance in this population. However, since, by design, all of the patients on
definitive 3GC therapy in the current study received intravenous 3GCs (predominantly ceftriaxone)
for at least the inpatient portion of therapy, these results should not be generalized to oral 3GCs.
Previous studies demonstrated oral beta-lactams were associated with the highest treatment failure
rates among all oral options in patients with gram-negative BSIs [18,19]. In addition, these data may
not be generalizable to CAE isolates that exhibit higher cefepime minimal inhibitory concentrations
(MICs) of 4 or 8 mcg/mL. Such isolates would be interpreted as being “susceptible dose-dependent”
to cefepime and recent data has shown that definitive cefepime therapy against such isolates was
associated with increased mortality compared to definitive carbapenem therapy [20]. It is unclear if
such an association extends to 3GC therapy, yet caution would be prudent until further research can be
performed in this subset of isolates.
Additional important considerations are the source of BSIs and the initial bacterial burden [11].
Primary sources in this cohort were the urinary system and central venous catheters (41.0% overall,
20.5% each). Urinary tract and central venous catheter infections are associated with a lower risk
of mortality than other sources of Gram-negative BSIs, as demonstrated in previous studies [21,22].
Relatively few patients in the current study had other sources of BSIs compared to prior studies by Chow
and colleagues (38.8% abdominal) or Kaye and colleagues (36.5% wounds, 24.9% respiratory) [5,6].
This difference may have been due to the current cohort representing not just university-affiliated
and tertiary care referral medical centers, but also community hospitals. Thus, the equivocal findings
of definitive 3GC therapy in the current study appear promising, particularly for uncomplicated
cases of CAE BSI. This should be a significant help to antimicrobial stewardship programs and others
attempting to spare widespread use of carbapenems and antipseudomonal beta-lactams. Additional
research is indeed warranted in patients with CAE BSI due to high mortality risk and/or uncontrolled
sources of CAE BSI, e.g., intraabdominal infections, meningitis, osteomyelitis, pneumonia, retained
prosthetic material. Carbapenems and other AmpC stable beta-lactams, such as cefepime, may continue
to be preferred in that setting until sufficient data in such patients are available. A recent cohort study
supports this caution, noting risk factors for relapsed or persistent BSIs with Enterobacter spp. were
immunosuppression or a line-associated source of BSIs [16]. The authors hypothesized delayed line
removal, i.e., an uncontrolled source, was the primary driver of the latter association. The current
study was designed to evaluate definitive antimicrobial therapy received after 72 h of collection of
index blood culture. Patients who did not survive the first 3 days of BSIs were not included in the
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study. This likely limited the study’s ability to detect previously established risk factors for mortality
such as malignancy, liver cirrhosis, source of BSI, and acute severity of illness [21,22].
The multicenter design represents the primary strength of this study. The large number of
patients with CAE BSI from 18 medical centers served to increase statistical power and generalizability.
These medical centers in the Southeastern Research Group Endeavor (SERGE-45) network included
a wider array of small community hospitals, which are typically underrepresented in the medical
literature. This makes the data more generalizable to a broader number of institutions across the
United States. However, the low incidence rate of BSIs secondary to Enterobacter species (3.3 per
100,000 person-years) and other CAE in population-based settings implied a relatively long study
period to accrue a sufficient number of patients [23]. Only 381 patients were enrolled, and only
65 patients (17%) received 3GCs for definitive therapy over an 8-year period. This highlights the
difficulty of conducting this type of research among sites that include community-based medical
centers. In addition, prescribers were less likely to use 3GCs for definitive therapy, particularly in
critically-ill patients or high mortality-risk infections, such as respiratory source and Enterobacter cloacae
BSI. This was likely influenced by healthcare providers’ awareness of prior literature and concern
regarding the use of 3GCs, especially in patients at high risk for treatment failure. Moreover, differences
in susceptibility reporting by each institution’s microbiology laboratory could have also impacted
the choice of definitive therapy as some hospitals may not report susceptibilities to 3GC due to the
same concerns. Other limitations include those inherent to retrospective, observation data collection,
such as missing data and the large variety of antibiotic agents used in each patient case. Outcome
assessments were limited by a lack of source control assessment in the retrospective chart review.
However, almost 40% were not amenable to source control (e.g., respiratory, other, unknown source).
A randomized clinical trial comparing ceftriaxone to a carbapenem for definitive therapy of CAE BSI
represents the ultimate design in order to eliminate confounding by indication, among other limitations
of observational cohort studies. However, the availability of very effective and highly bioavailable oral
options for treatment will make enrollment in such a clinical trial unattractive to the majority of patients
with BSI due to fluoroquinolone-susceptible organisms [18,19,24]. In addition, pharmacokinetic
differences between antimicrobial agents utilized were not assessed and, thus, meaningful conclusions
about dosing strategies in the 3GC group could not be made. Finally, potential AmpC production was
defined based on phenotypic rather than molecular testing methods.
4. Materials and Methods
4.1. Study Design and Population
This was a multicenter, retrospective, observational cohort study conducted in hospitalized
patients. Study sites were enrolled from within the SERGE-45 network and represented 18 institutions
from across the Southeast. The study protocol was approved by the local institutional review board
(IRB) within the Prisma Health System, which served as the coordinating site for the study (IRB
identification code Pro00039225, approval date 22 October 2014). Patients with blood cultures that
were positive for select CAE organisms (i.e., Enterobacter, Serratia, or Citrobacter spp.) between 1
January 2006 and 1 September 2014 were screened for study inclusion. This included Enterobacter
aerogenes (now known as Klebsiella aerogenes). The earliest positive blood culture was deemed the index
blood culture. Additional inclusion criteria were patient age ≥18 years and initiation of antibiotic
therapy following positive blood culture. Exclusion criteria included polymicrobial BSI based on the
index blood culture (exception: coagulase-negative Staphylococcus spp. or diphtheroids deemed a
contaminant, as suggested by the Infectious Diseases Society of America guidelines and the treatment
team), death prior to speciation or within 72 h of index blood culture, transfer from an outside hospital
with previous blood culture positive for target CAE organisms, pregnancy, incarceration, previous
study enrollment for a prior episode of BSI, or missing data that would preclude the appropriate
determination of a study group or primary endpoint [25].
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4.2. Study Definitions
CAE BSI was defined as the growth of Enterobacter spp., Serratia spp., or Citrobacter spp. in a blood
culture. Potential AmpC beta-lactamase production was based on phenotypic testing of bloodstream
isolates as previously defined [24]. Empiric therapy was defined as any antibiotic use within the first
72 h from the date/time of index blood culture collection, and definitive therapy was defined as any
antibiotic use thereafter (i.e., greater than 72 h after index blood culture). Definitive 3GC therapy was
specifically defined as any 3GC use (e.g., ceftriaxone, ceftazidime, cefotaxime) during the time period
greater than 72 h after index blood culture collection, whereas definitive non-3GC therapy was defined
as any antibiotic therapy which excluded 3GCs during the same period. Source of BSI was based on
physician documentation in the medical record. Source of infection other than urinary tract or CVC
was characterized as one variable based on prior evidence identifying this as a risk factor for mortality
in Gram-negative BSIs based on its association with a higher burden of infection [21,22].
Overall treatment failure was the primary composite endpoint consisting of in-hospital mortality,
hospital readmission within 30 days of hospital discharge, or recurrent infection with the same
organism within 90 days of hospital discharge (source of the infection may have differed). Adequate
therapy (modified from Cain et al.) [26] was determined as meeting each of the following criteria:
(1) antibiotic agent was administered intravenously, with the exception of oral fluoroquinolones which
were considered appropriate in hemodynamically stable patients due to high oral bioavailability,
and (2) the bloodstream isolate demonstrated in vitro susceptibility to at least one administered
antibiotic agent based on Clinical and Laboratory Standards Institute (CLSI) interpretive criteria.
Emergence of resistance was defined as an isolate that was initially susceptible to a specific antibiotic
agent, then became non-susceptible (i.e., intermediate or resistant) to the agent upon repeat culture of
the index organism.
4.3. Study Endpoints
The primary endpoint was overall treatment failure. Definitive 3GC therapy was compared to
definitive non-3GC therapy with an analysis of additional potential risk factors for OTF. Secondary
endpoints included the individual components of the composite endpoint of OTF as well as 30-day
mortality, hospital length of stay, and the emergence of antimicrobial resistance.
4.4. Microbiology Procedures & Data Management
Identification of bacterial isolates and antimicrobial susceptibility testing were performed at the
local microbiology laboratory for each participating medical center in accordance with CLSI guidelines.
Pharmacy and/or microbiology software systems at respective institutions were utilized to
retrospectively identify positive bloodstream cultures with Enterobacter, Serratia, and/or Citrobacter spp.
within the defined study period. Local electronic medical records at each study site were used to collect
patient data in a retrospective fashion for both study groups. REDCap™, an online data management
tool, was used for standardized data collection [27].
4.5. Statistical Analysis
Baseline categorical variables were analyzed via the chi-square test or Fisher’s exact test,
as appropriate. Baseline continuous variables were analyzed using Mann–Whitney U or Student’s t-test,
as appropriate. OTF was analyzed via Kaplan–Meier survival curves by therapy group. Univariable
and multivariable Cox proportional hazards regression was performed to evaluate the effect of definitive
3GC therapy on OTF, while controlling for potential confounders. Patients who did not experience
OTF during the study follow-up period were censored upon last documented interaction with the
healthcare system or at the end of the 90-day follow up period. Any covariate with a p-value ≤0.2
was included in the final regression model. Backward selection methods, along with findings from
the univariable analyses and published data determined a priori, were used to determine the most
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parsimonious model with the best fit of the data. Given the particularly notable risk of emergence of
resistance with Enterobacter spp. compared to other CAE [5,6,11], a post hoc sensitivity analysis on
the subgroup of patients with Enterobacter spp. BSI was performed for the primary endpoint of OTF.
Statistical analysis was performed using SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA).
For the primary endpoint of OTF, it was estimated the study would have to enroll 50 patients in
the definitive 3GC therapy group and 250 patients in the definitive non-3GC therapy group (N = 300
patients total with an estimated enrollment ratio of 1:5). This would provide 80% power to detect a
20% increase in the OTF rate in the definitive 3GC group vs. the definitive non-3GC therapy group,
assuming a baseline OTF rate of 25% in the definitive non-3GC therapy group and a two-sided alpha
level of 0.05. This delta was based on prior data demonstrating the rate of emergence of resistance was
19% with the use of broad-generation cephalosporins [6].
A STROBE statement outlining a completed checklist of items included in this report as a cohort
study is provided in the supplementary materials [28].
5. Conclusions
Our study demonstrates similar risk of overall treatment failure with definitive 3GC therapy
compared to other antimicrobial therapies for BSI due to select organisms with the potential to
produce AmpC (i.e., Enterobacter, Serratia, and Citrobacter spp.). These findings should prompt further
investigation into the role of third-generation cephalosporins in the treatment of infections with these
organisms. These may serve as important options to help spare widespread use of carbapenems and
other antipseudomonal beta-lactams.
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